Related references
Note: Only part of the references are listed.Heart Disease and Stroke Statistics-2009 Update A Report From the American Heart Association Statistics Committee and Stroke Statistics Subcommittee
Donald Lloyd-Jones et al.
CIRCULATION (2009)
SM16, an orally active TGF-β type I receptor inhibitor prevents myofibroblast induction and vascular fibrosis in the rat carotid injury model
Kai Fu et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2008)
Transforming growth factor beta inhibition increases mortality and left ventricular dilatation after myocardial infarction
Stefan Frantz et al.
BASIC RESEARCH IN CARDIOLOGY (2008)
Transforming Growth Factor-β Blockade Down-Regulates the Renin-Angiotensin System and Modifies Cardiac Remodeling after Myocardial Infarction
Leigh J. Ellmers et al.
ENDOCRINOLOGY (2008)
Macrophage roles following myocardial infarction
Jessica M. Lambert et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2008)
Oral administration of GW788388, an inhibitor of TGF-β type I and II receptor kinases, decreases renal fibrosis
M. Petersen et al.
KIDNEY INTERNATIONAL (2008)
Tranilast attenuates diastolic dysfunction and structural injury in experimental diabetic cardiomyopathy
Darren J. Kelly et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2007)
Endothelial-to-mesenchymal transition contributes to cardiac fibrosis
Elisabeth M. Zeisberg et al.
NATURE MEDICINE (2007)
Discovery of 4-{4-[3-(pyridin-2-yl)-1H-pyrazol-4-yl]pyridin-2-yl}-N-(tetrahydro-2H-pyran-4-yl)benzamide (GW788388):: A potent, selective, and orally active transforming growth factor-β type I receptor inhibitor
F Gellibert et al.
JOURNAL OF MEDICINAL CHEMISTRY (2006)
Load-sensitive measures may overestimate global systolic function in the presence of left ventricular hypertrophy: a comparison with load-insensitive measures
KA Connelly et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2006)
A direct interaction between TGFβ activated kinase 1 and the TGFβ type II receptor:: Implications for TGFβ signalling and cardiac hypertrophy
SJ Watkins et al.
CARDIOVASCULAR RESEARCH (2006)
Inhibition of protein kinase C reduces left ventricular fibrosis and dysfunction following myocardial infarction
AJ Boyle et al.
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY (2005)
Postinfarction gene therapy against transforming growth factor-β signal modulates infarct tissue dynamics and attenuates left ventricular remodeling and heart failure
H Okada et al.
CIRCULATION (2005)
Tranilast attenuates cardiac matrix deposition in experimental diabetes:: role of transforming growth factor-β
J Martin et al.
CARDIOVASCULAR RESEARCH (2005)
Fibrosis as a therapeutic target post-myocardial infarction
F See et al.
CURRENT PHARMACEUTICAL DESIGN (2005)
Tranilast attenuates structural and functional aspects of renal injury in the remnant kidney model
DJ Kelly et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2004)
Inhibition of TGF-β signaling exacerbates early cardiac dysfunction but prevents late remodeling after infarction
M Ikeuchi et al.
CARDIOVASCULAR RESEARCH (2004)
Progression from compensated hypertrophy to failure in the pressure-overloaded human heart -: Structural deterioration and compensatory mechanisms
S Hein et al.
CIRCULATION (2003)
Transforming growth factor-β function blocking prevents myocardial fibrosis and diastolic dysfunction in pressure-overloaded rats
F Kuwahara et al.
CIRCULATION (2002)
Inhibition of transforming growth factor (TGF)-β1-induced extracellular matrix with a novel inhibitor of the TGF-β type I receptor kinase activity:: SB-431542
NJ Laping et al.
MOLECULAR PHARMACOLOGY (2002)
Postinfarction left ventricular remodelling: where are the theories and trials leading us?
ZR Yousef et al.
HEART (2000)
Induction of cardiac fibrosis by transforming growth factor-beta(1)
PJ Lijnen et al.
MOLECULAR GENETICS AND METABOLISM (2000)